Overview
Status
Active
Registry date
2017-09-21
Share capital
5,000.00 PLN
Registered address
ul. Zygmunta Radnickiego 11, 30-498 Kraków, Poland
Financials
Revenue history (in k)
Filing timeliness
No financial statement for 2023 – the filing deadline has passed. 5 of 5 financial statements were filed late (the longest delay 1213 days for 2018).
- 2023not filed
- 202204/06/2024
- 202104/06/2024
- 202004/06/2024
- 201909/11/2022
- 201809/11/2022
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2022.
Division · Manufacture of basic pharmaceutical products and pharmaceutical preparations161 / 330
Top 49%
Voivodeship · Małopolskie13,635 / 46,035
Top 30%
Country · Poland150,838 / 495,860
Top 30%
Results vs industry
Revenue
This companyUSD 597.78kMedianUSD 919.05kAverageUSD 25.83m
Net profit
This companyUSD 85.21kMedianUSD 14.92kAverageUSD 2.77m
Operating costs
This companyUSD 503.54kMedianUSD 873.06kAverageUSD 21.43m
Assets
This companyUSD 800.55kMedianUSD 897.46kAverageUSD 31.52m
Industry
Authorized Representatives
Witold Antoni Maleszka – President of the Management Board
Manner of representation
The company may be represented by each member of the management board independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Witold Antoni Maleszkaage 54 | 100 | $1,350.62 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
Smart Bioticssp. z o.o. | 1,620.75 USD | 60% |
Bank accounts
Registered as a VAT taxpayer on 2017-10-12.
84 1090 1665 0000 0001 3503 9580
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Instytut Biotechnologii Surowic i Szczepionek Biomed - Skrót Firmy Ibss BiomedS.A. | $37,103,878.54 | biomed.pl | ||
| Fagronsp. z o.o. | $21,715,187.73 | fagron.pl | ||
| Krakowskie Zakłady Zielarskie Herbapol w KrakowieS.A. | $7,294,338.51 | herbapol.krakow.pl | ||
| Biomarsp. z o.o. | $909,113.28 | biomar.pl | ||
| Przedsiębiorstwo Farmaceutyczne Leki Natury Tadeusz Polańskisp. z o.o. | $893,738.50 | lekinatury.pl | ||
| Human BiomeS.A. | $888,361.19 | human-biome.com | ||
| Zeptor Polskasp. z o.o. | $748,374.79 | zeptor.pl | ||
| DR Andresp. z o.o. | $453,987.42 | drandre.pl | ||
| F1 PharmaS.A. | $272,113.66 | f1pharma.pl | ||
| Zakład Farmaceutyczny Amarasp. j. | $0.00 | amara.pl |
FAQ
The main business activity of Detrapharm focuses on manufacture of pharmaceutical preparations.
The company was registered in the Polish National Court Register (KRS) on September 21, 2017.
The headquarters is located at: ul. Zygmunta Radnickiego 11, 30-498 Kraków.
The management board consists of: Witold Antoni Maleszka (President of the Management Board).
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2022 to December 31, 2022.
In 2022, the company generated total revenue of $597,785, representing an increase of 45.1% compared to 2021.
Yes, in 2022 the company was profitable, achieving a net profit of $85,215, meaning the company increased its profit by 345.8%.
The largest operating cost category falls under other operating costs. This category amounted to $419,635 in 2022, representing 83% of all operating expenses.
Last updated: 2026-10-07